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ABSTRACT  
Objectives: To determine the trends of antibiotic resistance of Gram-negative bacteria most frequently isolated 
from inpatients at the University of Science and Technology Hospital (USTH) in Sana'a, Yemen.  
Methods: A retrospective, cross-sectional study on the antibiotic resistance of Gram-negative bacteria most fre-
quently isolated from respiratory tract, pus, urine, blood and other types of specimens from inpatients admitted 
to the USTH. Data were retrieved from the hospital records of culture-positive inpatients in the period from Jan-
uary 2006 to December 2013, and annual trends of resistance were compared using chi-square test for trends at 
P values < 0.05. 
Results: Of 2005 Gram-negative bacterial isolates in the period from 2006 to 2013, the most frequently isolated 
species were Escherichia coli (41.6%), Acinetobacter species (26.7%), Klebsiella species (21.0%) and Pseudomo-
nas aeruginosa (10.6%). Amikacin and carbapenems were the most active drugs against E. coli, with a decrease 
in the susceptibility of this species to the third- and fourth-generation cephalosporins and a variable resistance 
rate to quinolones that significantly increased in 2013. Acinetobacter species susceptibility to most antibiotics 
decreased significantly over the years of the study, where polymyxin B was the only one found to be effective 
against this species. On the other hand, the trend of Klebsiella species resistance to imipenem, piperacillin-
tazobactam, cefepime, ceftazidime increased over the years of the study. Susceptibility of Klebsiella species to 
ciprofloxacin, levofloxacin and moxifloxacin showed fluctuations, while the susceptibility of aminoglycosides 
(amikacin and gentamicin) and ampicillin-sulbactam showed no difference. The resistance of P. aeruginosa to 
the majority of antibiotics was not dramatically changed over the years of the study period, but gentamicin re-
sistance rate was considerably dropped from 77.8% in 2008 to 25.9% in 2013. 
Conclusions: Of the most frequently isolated Gram-negative bacteria in Sana'a, Acinetobacter species have the 
highest resistance rate to the most commonly used antibiotics, where only polymyxin B is effective against this 
species. P. aeruginosa shows an unchanging rate of resistance to antibiotics in the USTH despite being quite re-
sistant to antibiotics on a global scale, which could be attributed to the smaller number of P. aeruginosa isolates 
tested over the study period. Further large-scale studies on the trends of antibiotic resistance rates in hospital-
based settings and the best ways to counteract such resistance in Yemen are recommended. 
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1. Introduction 
Resistance of bacteria to antibiotics is usually 
caused by genetic modifications as a result of the 
irrational use of antibiotics. Gram-negative bacte-
ria are one of the most common causes of infec-
tions in clinical settings (1, 2). They cause at least 
30% of hospital-acquired infections and about 15-
20% of meningitis in adults (3, 4). In the United 
States, Gram-negative bacteria cause about 70% 
of infections in intensive care units (ICUs). Fur-
thermore, they are the most common cause of 
bloodstream infections, lower respiratory tract 
infections and urinary tract infections in ICUs (5–
8). Decreased susceptibility of Gram-negative bac-
teria to commonly used antibiotics poses serious 
threats to the public health, leading to an increase 
in medical care cost, prolonged hospital length of 
stay, treatment failure and death (9–12). For ex-
ample, in the United States, more than 23,000 
deaths per year have been attributed to infections 
by antibiotic-resistant bacteria. In addition, the 
overall cost resulting from antibiotic resistance 
has been estimated to be $20 billion a year for 
healthcare costs and up to $35 billion a year for 
the society (13). 
In addition to the health and economic conse-
quences of antibiotic resistance, a few new anti-
microbials have been developed and approved 
over the past three decades, limiting the options 
to treat antibiotic-resistant bacteria (13, 14). The 
decline in the development of antibiotics is due to 
several factors, including the high cost required 
for drug development, relatively low rate of re-
turn on investment in antibiotics, challenges to 
screening for new compounds, decreased antibi-
otic longevity as a result of resistance emergence 
and unavailability of formal guidelines to evaluate 
antibiotic effectiveness and safety issues of new 
antimicrobial drugs (15–19). 
Variations in antibiotic resistance among 
different institutions and countries highlight 
the importance of the localized antibiotic re-
sistance data in choosing the most appropriate 
empirical therapy for nosocomial infections (20). 
In Yemen, data on antibiotic resistance are very 
limited, particularly among inpatients. Therefore, 
the aim of the present study was to determine the 
trends to antibiotic resistance of Gram-negative 
bacteria most frequently isolated from inpatients 
admitted to the University of Science and Technol-
ogy Hospital (USTH) in Sana’a city, Yemen. 
2. Methods 
2.1. Study design and setting 
This retrospective, cross-sectional study was con-
ducted in the USTH, a private tertiary care hospital 
with a 200-bed capacity. Inpatient departments in-
cluded in the study were medical and surgical 
wards (for males and females), ICUs, and Coronary 
Care Unit. 
2.2. Data collection 
Data were retrieved from the hospital records of 
culture-positive inpatients admitted to the USTH 
in the period from January 01, 2006 to December 
31, 2013. Only positive culture results of sputum, 
pus, urine, blood, wound, and other specimens for 
Gram-negative bacteria, which were isolated from 
patients older than 18 years and underwent 
standard cultivation and biochemical as well as an-
tibiotic susceptibility testing, were included in this 
study. Data were collected on the susceptibility of 
bacterial isolates to the following antibiotics: 
imipenem, meropenem, piperacillin-tazobactam, 
cefepime, ceftazidime, ciprofloxacin, levofloxacin, 
moxifloxacin, amikacin, gentamicin, ampicillin-
sulbactam,  cefoperazone-sulbactam, and polymyx-
in (HIMEDIA Laboratories, Mumbai, India). 
2.3. Data analysis  
Antibiotic resistance of Gram-negative bacteria 
was presented as percentages of the total number 
of isolates per year. Data were analyzed using IBM 
SPSS Statistics for Windows, version 20.0 (IBM 
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Corp., Armonk, NY, USA), where annual trends 
of resistance were compared using chi-square 
test for trends. Differences at P values < 0.05 
were considered to be statistically significant. 
3. Results 
Table (1) shows that of 2005 Gram-negative 
bacterial isolates in the period from 2006 to 
2013, the most frequently isolated species were 
Escherichia coli (41.6%), Acinetobacter species 
(26.7%), Klebsiella species (21.0%) and Pseu-
domonas aeruginosa (10.6%). Regarding the 
origin of Gram-negative isolates, Table (2) 
shows that respiratory tract specimens 
(31.8%), pus (19.7%), urine (17.3%) and blood 
(14.2%) were the most frequent sources of the 
isolates. E. coli was most frequently isolated 
from urine (72.1%; 251/348), pus (58.5%; 
231/395) and blood (42.1%; 120/285), while 
Acinetobacter species was most frequently iso-
lated from respiratory tract specimens (47.9%; 
305/637). Respiratory tract specimens, pus and 
blood were the most common sources for 
Klebsiella species, while P. aeruginosa was most 
frequently isolated from respiratory tract and 
pus specimens (Table 2). 
3.1. Resistance pattern of E.coli 
Amikacin and carbapenems were the most ac-
tive drugs against E. coli (Table 3). For extend-
ed-spectrum penicillin, the susceptibility of E. 
coli was good until 2012, but resistance rate 
reached to 27.5% in 2013. A decrease in the 
susceptibility to the third- and fourth-
generation cephalosporins was also observed 
for E. coli. The resistance rate of E. coli to quin-
olones was variable, but it significantly in-
creased in 2013 (p <0.001) (Table 3).  
3.2. Resistance pattern of Acinetobacter species 
The susceptibility of Acinetobacter species to 
most antibiotics decreased significantly over 
the years of the study (Table 4). Although no 
significant difference was found in the resistance 
rate of Acinetobacter species to meropenem (p = 
0.061) and gentamicin (p = 0.774), both did not 
show an acceptable activity over the years of the 
study. Of all tested antibiotics, polymyxin B was 
the only one found to be effective against Acineto-
bacter species (Table 4). 
3.3. Resistance pattern of Klebsiella species 
The trend in the resistance of Klebsiella species to 
imipenem (p <0.001), piperacillin-tazobactam (p 
<0.001), cefepime (p = 0.004), ceftazidime (p = 
0.007) increased over the years of the study period 
(Table 5). Susceptibility to ciprofloxacin, levofloxa-
cin and moxifloxacin showed fluctuations, while 
the susceptibility of aminoglycosides (amikacin 
and gentamicin) and ampicillin-sulbactam showed 
no difference (p = 0.151), (p = 0.062) and (p = 
0.359) respectively.  
3.4. Resistance pattern of P. aeruginosa 
The resistance of P. aeruginosa was not dramati-
cally changed to the majority of antibiotics over 
the years of the study period (Table 6). Neverthe-
less, gentamicin resistance rate was considerably 
dropped from 77.8% in 2008 to 25.9% in 2013 (p 
= 0.004).    
4. Discussion 
Gram-negative bacteria were most frequently iso-
lated from respiratory tract specimens of inpa-
tients admitted to the USTH followed by those iso-
lated from pus, urine, and blood. In contrast, other 
epidemiological studies elsewhere reported urine 
as the most frequent source of Gram-negative bac-
teria, with a variability in the distribution pattern 
of Gram-negative bacteria in other specimens such 
as blood, wound and sputum (1, 21–23). It is to be 
noted that the variability in the most frequent 
sources of Gram-negative bacteria among different 
institutions and countries is expected. 
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Table 1. Gram-negative bacterial isolates from inpatients in the USTH, Sana’a (2006–2013) 
Isolated bacteria 
Number of isolates Total 
n (%) 2006 2007 2008 2009 2010 2011 2012 2013 
E. coli 44 67 69 117 105 128 164 140 834 (41.6) 
Acinetobacter species 1 6 42 115 95 98 82 97 536 (26.7) 
Klebsiella species 18 33 30 39 57 52 115 78 422 (21.0) 
P. aeruginosa 5 19 13 31 40 34 40 31 213 (10.6) 
Total 68 125 154 302 297 312 401 346 2005 




Frequency of isolates per year Total 




E. coli 3 (20.0) 3 (11.5) 8 (17.0) 12 (13.8) 15 (13.0) 9 (9.5) 22 (17.5) 25 (19.8) 97 (15.2) 
Klebsiella species 10 (66.6) 14 (53.8) 13 (27.7) 19 (21.8) 28 (24.3) 19 (20.0) 37 (29.4) 27(21.4) 167 (26.2) 
P. aeruginosa 1 (6.6) 8 (30.7) 5 (10.6) 7 (8.0) 16 (13.9) 14 (14.7) 8 (6.3) 9 (7.1) 68 (10.7) 
Acinetobacter species 1 (6.6) 1 (3.8) 21 (44.7) 49 (56.3) 56 (48.7) 53 (55.8) 59 (46.8) 65 (51.6) 305 (47.9) 
Total 15 ( 2.4) 26 (4.1) 47 (7.3) 87 (13.6) 115 (18.0) 95 (15.0) 126 (19.8) 126 (19.8) 637 (100.0) 
Pus# 
 
E. coli 8(88.9) 16 (59.6) 13 (72.2) 28 (66.7) 16 (37.2) 48 (57.8) 66(57.8) 36 (57.1) 231 (58.5) 
Klebsiella species 0 (0.0) 4 (17.4) 0 (0.0) 3 (7.1) 12 (27.9) 8 (9.6) 28 (24.6) 15 (23.8) 70 (17.7) 
P. aeruginosa 1 (11.1) 3 (13.0) 3 (16.7) 4 (9.5) 8 (18.6) 11 (13.3) 11 (9.6) 3 (4.8) 44 (11.1) 
Acinetobacter species 0 (0.0) 0 (0.0) 2 (11.1) 7 (16.7) 7 (16.3) 16 (19.3) 9 (7.9) 9 (14.3) 50 (12.6) 
Total 9 (2.3) 23 (5.8) 18 (4.5) 42 (10.6) 43 (10.9) 83 (21.0) 114 (28.9) 63 (16.0) 395 (100.0) 
Urine 
E. coli 15(83.3) 29(80.6) 29(65.9) 36(72.0) 42(77.8) 31(67.4) 27(64.3) 42(72.4) 251 (72.1) 
Klebsiella species 3(16.7) 4(11.1) 7(15.9) 3(6.0) 4(7.4) 8(17.4) 7(16.7) 10(17.2) 46 (13.2) 
P. aeruginosa 0(0.0) 2(5.5) 3(6.8) 3(6.0) 4(7.4) 5(10.9) 7(16.7) 4(6.9) 28 (8.0) 
Acinetobacter species 0(0.0) 1(2.8) 5(11.4) 8(16.0) 4(7.4) 2(4.3) 1(2.4) 2(3.4) 23 (6.6) 
Total 18(5.2 ) 36(10.3) 44(12.6) 50(14.4) 54(15.5) 46(13.2) 42(12.1) 58(16.7) 348(100.0) 
Blood 
E. coli 7(87.5) 7(38.9) 10(43.5) 21(37.5) 21(38.9) 11(39.3) 24(48.0) 19(39.6) 120 (42.1) 
Klebsiella species 1(12.5) 7(38.9) 5(21.7) 5(8.9) 8(14.8) 7(25.0) 17(34.0) 17(35.4) 67 (23.5) 
P. aeruginosa 0(0.0) 3(16.6) 0(0.0) 3(5.4) 3(5.5) 1(3.6) 1(2.0) 4(8.3) 15 (5.3) 
Acinetobacter species 0(0.0) 1(5.5) 8(34.8) 27(48.2) 22(40.7) 9(32.1) 8(16.0) 8(16.7) 83 (29.1) 
Total 8(2.8) 18(6.3) 23(8.1) 56(19.7) 54(19.0) 28(9.8) 50(17.5) 48(16.8) 285(100.0) 
Wound 
E. coli 4(66.7) 4(66.7) 2(40.0) 8(23.5) 1(20.0) 16(57.1) 16(47.1) 5(33.3) 56 (42.1) 
Klebsiella species 2(33.3) 1(16.7) 3(60.0) 5(14.7) 1(20.0) 4(14.3) 13(38.2) 5(33.3) 34 (25.6) 
P. aeruginosa 0(0.0) 0(0.0) 0(0.0) 10(29.4) 1(20.0) 3(10.7) 4(11.8) 0(0.0) 18 (13.5) 
Acinetobacter species 0(0.0) 1(66.7) 0(0.0) 11(32.4) 2(40.0) 5(17.9) 1(2.9) 5(33.3) 25 (18.8) 
Total 6(4.5) 6(4.5) 5(3.7) 34(25.6) 5(3.7) 28(21.1) 34(25.6) 15(11.3) 133(100.0) 
Other 
E. coli 7(58.3) 8(50.0) 7(41.2) 12(36.4) 10(38.5) 13(40.6) 9(25.7) 13(36.1) 79 (38.2) 
Klebsiella species 2(16.7) 3(18.75) 2(11.7) 4(12.1) 4(15.4) 6(18.7) 13(37.1) 4(11.1) 38 (18.3) 
P. aeruginosa 3(25.0) 3(18.5) 2(11.7) 4(12.1) 8(30.7) 0(0.0) 9(25.7) 11(30.6) 40 (19.3) 
Acinetobacter species 0(0.0) 2(12.5) 6(35.3) 13(39.4) (15.4) 13(40.6) 4(11.4) 8(22.2) 50 (24.1) 
Total 12(5.8) 16(7.7) 17(8.2) 33 (15.9) 26(12.6) 32(15.5) 35(16.9) 36 (17.4) 207(100.0) 
* The majority of respiratory tract samples were sputum, while the minority was respiratory tubes. 
# Pus samples were mainly exudates collected from prospective wounds or abscesses.  
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Table 3. Trends of E. coli resistance to antibiotics isolated from different clinical samples collected from inpatients admitted to the USTH, Sana'a (2006–
2013) 
Antibiotic 
E. coli resistance to antibiotics per year 
Number of isolates (resistance %) P value Trend 
2006 2007 2008 2009 2010 2011 2012 2013 
Imipenem 23(0.0) 66(5.1) 63(0.0) 101(0.0) 105(3.8) 126(1.6) 155(0.6) 134(9.7) 0.001 ↑ 
Meropenem --(ND) 8(0.0) 28(0.0) 15(0.0) --(ND) --(ND) 29(0.0) 57(14.0) 0.009 ↑ 
Pipracillin-tazobactam 8(0.0) 54(1.9) 60(10.0) 105(1.9) 86(2.3) 121(5.8) 164(9.8) 138(27.5) <0.001 ↑ 
Cefepime --(ND) 2(100.0) 17(58.8) 58(32.8) 46(76.1) 123(81.3) 156(70.5) 131(84.0) <0.001 ↑ 
Ceftazidim 38(44.7) 57(35.1) 63(30.2) 95(35.8) 98(45.9) 120(68.3) 148(64.2) 139(82.7) <0.001 ↑ 
Ciprofloxacin 35(60.0) 48(52.1) 59(52.5) 66(57.6) 76(75.0) 119(72.3) 152(65.1) 122(82.0) <0.001 ↑ 
Levofloxacin --(ND) 25(28.0) 10(40.0) 43(37.2) 81(71.6) 118(49.2) 153(53.6) 92(71.7) <0.001 ↑ 
Moxifloxacin --(ND) --(ND) 8(25.0) 21(33.3) 50(46.0) 112(74.1) 152(69.1) 63(81.0) <0.001 ↑ 
Amikacin 24(12.5) 45(2.2) 40(10.0) 80(5.0) 77(3.9) 125(0.8) 157(1.9) 133(3.0) 0.014 ↓ 
Gentamicin 25(64.0) 43(39.5) 60(43.3) 30(66.7) 52(48.1) 120(40.0) 156(34.0) 119(41.2) 0.021 ↑ 
Ampicillin-sulbactam --(ND) 30(83.3) 29(89.7) 65(92.3) 4(75.0) --(ND) 2(100.0) 34(76.5) 0.171 – 
Cefoperazone-sulbactam --(ND) 15(26.7) 24(0.0) --(ND) 4(0.0) 122(13.9) 151(9.3) 83(16.9) 0.696 – 
Polymyxin --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) NA NA 
ND, not determined; NA, not applicable. 
Table 4. Trends of Acinetobacter species resistance to antibiotics isolated from different clinical samples collected from inpatients admitted to the USTH, 
Sana'a (2006–2013) 
Antibiotic 
Acinetobacter species resistance to antibiotics per year 
Number of isolates (resistance %) P value Trend 
2006 2007 2008 2009 2010 2011 2012 2013 
Imipenem 1(0.0) 6(16.7) 40(52.5) 90(55.6) 75(46.7) 88(80.7) 79(87.3) 97(82.5) <0.001 ↑ 
Meropenem --(ND) 4(100.0) 16(50.0) 19(94.7) --(ND) --(ND) 14(92.9) 2(100.0) 0.061 - 
Pipracillin-tazobactam 1(0.0) 6(0.0) 18(77.8) 100(46.0) 78(11.5) 89(62.9) 77(88.3) 76(86.8) <0.001 ↑ 
Cefepime --(ND) 3(100.0) 12(91.7) 53(88.7) 34(85.3) 94(100.0) 75(98.7) 96(99.0) <0.001 ↑ 
Ceftazidim 1(100.0) 3(66.7) 40(82.5) 88(69.3) 88(83.0) 93(98.9) 80(95.0) 97(99.0) <0.001 ↑ 
Ciprofloxacin 1(100.0) 6(33.3) 25(64.0) 68(85.3) 71(83.1) 90(96.7) 64(100.0) 83(100.0) <0.001 ↑ 
Levofloxacin --(ND) 1(0.0) 7(71.4) 44(56.8) 70(72.9) 92(41.3) 78(60.3) 78(88.5) 0.004 ↑ 
Moxifloxacin --(ND) --(ND) 7(57.1) 27(40.7) 41(41.5) 92(79.3) 69(98.6) 34(94.1) <0.001 ↑ 
Amikacin --(ND) 1(0.0) 27(59.3) 73(56.2) 71(53.5) 94(75.5) 78(76.9) 71(73.2) 0.001 ↑ 
Gentamicin 1(0.0) 5(80.0) 34(64.7) 30(86.7) 44(90.9) 87(86.2) 76(71.1) 76(75.0) 0.774 - 
Ampicillin-sulbactam --(ND) 4(75.0) --(ND) 60(76.7) 2(100.0) --(ND) 2(100.0) 41(95.1) 0.011 ↑ 
Cefoperazone-sulbactam --(ND) 2(50.0) 18(5.6) 26(7.7) 5(100.0) 90(78.9) 79(78.5) 79(69.6) <0.001 ↑ 
Polymyxin --(ND) --(ND) 7(28.6) 42(14.3) 27(11.1) 93(1.1) 81(0.0) 90(0.0) <0.001 ↓ 
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Table 5. Trends of Klebsiella species resistance to antibiotics isolated from different clinical samples collected from inpatients admitted to the USTH, Sana'a 
(2006–2013) 
Antibiotic 
Klebsiella species resistance to antibiotics per year 
Number of isolates (resistance %) P value Trend 
2006 2007 2008 2009 2010 2011 2012 2013 
Imipenem 11(9.1) 28(0.0) 29(10.3) 37(5.4) 55(1.8) 50(4.0) 114(14.9) 74(23.0) <0.001 ↑ 
Meropenem --(ND) 5(0.0) 2(0.0) 13(15.4) --(ND) --(ND) 28(17.9) 30(33.3) 0.059 - 
Pipracillin-tazobactam 4(0.0) 31(0.0) 25(4.0) 36(16.7) 49(2.0) 52(13.5) 113(41.6) 77(49.4) <0.001 ↑ 
Cefepime --(ND) --(ND) 8(75.0) 23(56.5) 34(58.8) 47(70.2) 110(75.5) 77(83.1) 0.004 ↑ 
Ceftazidim 14(64.3) 24(54.2) 29(82.8) 30(73.3) 50(56.0) 50(60.0) 105(79.0) 78(84.6) 0.007 ↑ 
Ciprofloxacin 14(28.6) 18(27.8) 25(44.0) 30(23.3) 41(46.3) 49(46.9) 93(60.2) 66(50.0) 0.001 ↑ 
Levofloxacin --(ND) 9(22.2) 7(42.9) 11(27.3) 40(37.5) 47(17.0) 98(46.9) 55(50.0) 0.018 ↑ 
Moxifloxacin --(ND) --(ND) 8(37.5) 5(40.0) 22(27.3) 46(34.8) 96(68.8) 34(58.8) 0.001 ↑ 
Amikacin 9(0.0) 19(5.3) 18(22.2) 24(12.5) 48(0.0) 50(8.0) 110(10.9) 74(16.2) 0.151 - 
Gentamicin 16(56.3) 24(70.8) 22(68.2) 7(100.0) 38(42.1) 43(55.8) 103(49.5) 66(53.0) 0.062 - 
Ampicillin-sulbactam --(ND) 11(90.9) 11(100.0) 20(90.0) --(ND) --(ND) 1(100.0) 29(86.2) 0.359 - 
Cefoperazone-sulbactam --(ND) 11(9.1) 18(5.6) 6(16.7) 1(0.0) 47(14.9) 103(46.6) 49(53.1) <0.001 ↑ 
Polymyxin --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) NA NA 
ND, not determined; NA, not applicable. 
 
Table 6. Trends of P. aeruginosa resistance to antibiotics isolated from different clinical samples collected from inpatients admitted to the USTH, Sana'a 
(2006–2013) 
Antibiotic 
P. aeruginosa resistance to antibiotics per year 
Number of isolates (resistance %) P value Trend 
2006 2007 2008 2009 2010 2011 2012 2013 
Imipenem 4(0.0) 18(11.1) 11(36.4) 14(42.9) 38(7.9) 33(15.2) 40(15.0) 28(39.3) 0.296 - 
Meropenem --(ND) 3(0.0) 6(16.7) 5(40.0) --(ND) --(ND) 6(33.3) 13(30.8) 0.391 - 
Pipracillin-tazobactam 3(0.0) 19(0.0) 13(23.1) 30(16.7) 37(10.8) 32(6.3) 39(15.4) 29(20.7) 0.194 - 
Cefepime --(ND) 1(0.0) 3(66.7) 15(33.3) 20(40.0) 32(40.6) 38(34.2) 31(32.3) 0.576 - 
Ceftazidim 4(25.0) 17(23.5) 10(50.0) 28(32.1) 35(31.4) 34(26.5) 19(36.8) 30(53.3) 0.110 - 
Ciprofloxacin 5(60.0) 14(28.6) 13(46.2) 24(25.0) 25(40.0) 31(16.1) 37(21.6) 24(41.7) 0.370 - 
Levofloxacin --(ND) 8(37.5) 1(0.0) 20(30.0) 18(33.3) 31(19.4) 36(19.4) 17(47.1) 0.934 - 
Moxifloxacin --(ND) --(ND) 2(50.0) 9(22.2) 13(46.2) 31(19.4) 36(47.2) 11(54.5) 0.159 - 
Amikacin 2(50.0) 14(0.0) 8(37.5) 19(5.3) 36(5.6) 34(11.8) 39(10.3) 28(35.7) 0.063 - 
Gentamicin 5(60.0) 13(30.8) 9(77.8) 13(46.2) 24(33.3) 33(18.2) 39(17.9) 27(25.9) 0.004 ↓ 
Ampicillin-sulbactam --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) NA NA 
Cefoperazone-sulbactam --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) NA NA 
Polymyxin --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) --(ND) NA NA 
ND, not determined; NA, not applicable.
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The most frequently isolated species from the 
inpatients admitted to the departments of the 
USTH were E. coli (41.6%) and Acinetobacter 
species (26.7%) followed by Klebsiella species 
(21.0%) and P. aeruginosa (10.6%). In line with 
these findings, E. coli was the most frequently iso-
lated species in Iran (71.9%), Saudi Arabia 
(38.3%) and Rwanda (35.7%). Nonetheless, 
Klebsiella species was the second most frequently 
isolated bacteria in the above-mentioned coun-
tries (1, 22, 23).  
The present study showed an emerging crisis of 
antibiotic resistance among the most isolated 
Gram-negative bacteria, where the highest rate of 
resistance was observed for Acinetobacter species 
that presented a dramatically rising trend of re-
sistance to most antibiotics. Only polymyxin re-
mains active against Acinetobacter species. This 
finding is consistent with that reported from China, 
where the susceptibility of Acinetobacter baumannii 
to most antibiotics, including cephalosporins, quin-
olones, aminoglycosides and carbapenems, de-
creased over a four-year period  (24). However, 
polymyxin was not tested in the latter study.  
Resistance of E. coli and Klebsiella species to 
fluoroquinolones, piperacillin-tazobactam, 
ceftazidime and cefepime increased significantly 
over the years, while only amikacin was activity 
against these two species. This finding is similar 
to that reported from Rwanda, where E. coli and 
Klebsiella species had a high resistance rate to 
penicillins, quinolones and the third-generation 
cephalosporins (23). In contrast to the findings of 
the present study, gentamicin and ciprofloxacin 
still showed a reasonable activity against E. coli 
in northern Ethiopia (25). 
In the present study, the unchanging re-
sistance rate of P. aeruginosa to most antibiotics 
could be contributed to the small number of iso-
lates in the USTH over the years of the study. 
However, P. aeruginosa is one of the most antibi-
otic-resistant bacteria worldwide, contributing to 
ICU-acquired infections with limited empirical 
therapy options (26, 27). In contrast, the suscep-
tibility of P. aeruginosa to gentamicin, ceftazidime 
and ciprofloxacin decreased significantly in Saudi 
Arabia, while the trend of resistance to car-
bapenems, amikacin and piperacillin-tazobactam 
was not dramatically changed over a 7-year peri-
od (1998-2004) (28). In the United States, the 
National Nosocomial Infection Surveillance 
(NNIS) survey data of the Centers for Disease 
Prevention and Control found a dramatic de-
crease in the susceptibility rate of P. aeruginosa 
to both imipenem and quinolones (29). 
The present study demonstrated that Gram-
negative bacterial isolates have high incidence of 
resistance to commonly used antibiotics among 
inpatients admitted to the USTH. All bacterial iso-
lates showed an elevated rate of resistance to 
third- and fourth-generation cephalosporins and 
quinolones. Several factors could contribute to 
such an increased rate of resistance including 
misuse of antibiotics by healthcare providers, 
lack of surveillance data that would be helpful for 
choosing proper empirical therapy and use of 
broad-spectrum antibiotics for a long duration 
(more than 7 days).  
Although this study provides data on antibi-
otic resistance over an eight-year period from 
one of the leading healthcare hospitals in Sana'a, 
it has a number of limitations. First, not all anti-
biotics were tested with the same frequency of 
isolates. Second, antibiotic susceptibility was 
tested for all inpatients, including those in ICU. 
This, in turn, may lead to an over estimation of 
the antibiotic resistance rate because most ICU 
patients usually have more virulent bacterial in-
fections than those in other inpatient depart-
ments as a result of co-morbidities, more fre-
quent use of mechanical ventilation and intravas-
cular devices. Furthermore, due to the limited 
availability of resources at the time of the study, 
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only data in the period from 2006 to 2013 were 
analyzed. 
5. Conclusions 
Antibiotic resistance is a recognizable problem 
among inpatients admitted to different depart-
ments of tertiary care hospitals and centers. Of 
the most frequently isolated Gram-negative bac-
teria, Acinetobacter species has the highest re-
sistance rate to the most commonly used antibi-
otics, where only polymyxin B is effective against 
this species. P. aeruginosa shows an unchanging 
rate of resistance to antibiotics in the USTH de-
spite being quite resistant to antibiotics on a 
global scale, which could be attributed to the 
smaller number of P. aeruginosa isolates tested 
over the study period. Further large-scale studies 
on the trends of antibiotic resistance rates in 
hospital-based settings and the best ways to 
counteract such resistance in Yemen are recom-
mended. 
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